SOAT1 and metabolic dysfunction-associated steatotic liver disease: Pathways that were decreased in the WM group included lipid-related pathways (adipocytokine signaling, non-alcoholic fatty liver disease), as well as pathways known to support tumor growth (MAPK, PI3K/Akt, Ras, JAK/STAT signaling) (Fig. 3E).